A series of novel isoxazole functionalized pyrazolo[3,4‐b]pyridine derivatives 5a‐n were prepared, respectively, initiated from 6‐thiophenyl‐4‐(trifluoromethyl)‐1H ‐pyrazolo[3,4‐b ]pyridin‐3‐amine 3 through selective N ‐propargylation, and these N ‐propargylated compounds 4 were cyclized with aryloximes by using of sodium hypochlorite, and obtained the title products 5a‐n . All the final products 5a‐n were submitted for anticancer activity against four cancer cell lines such as “HeLa—cervical cancer (CCL‐2); COLO 205—colon cancer (CCL‐222); HepG2—liver cancer (HB‐8065); MCF7—breast cancer (HTB‐22)”; Compounds 5c , 5d , and 5h are found to have more prominent anticancer activity at micro molar concentration.

中文翻译：

---

新型异恶唑官能化的吡唑并[3,4-b]吡啶衍生物的合成；他们的抗癌活性

一系列新颖的异恶唑官能吡唑并[3,4-b]吡啶衍生物的图5a-n的制备，分别从6-噻吩基-4-（三氟甲基）-1发起ħ -吡唑并[3,4- b ]吡啶-3-胺3通过选择性N炔丙基化，而这些N炔丙基化的化合物4通过使用次氯酸钠与芳基肟环合，获得标题产物5a-n。所有最终产品5a‐n已提交针对四种癌细胞系（例如“ HeLa-宫颈癌（CCL-2）”）的抗癌活性；COLO 205-结肠癌（CCL‐222）；HepG2-肝癌（HB-8065）；MCF7-乳腺癌（HTB-22）”；发现化合物5c，5d和5h在微摩尔浓度下具有更突出的抗癌活性。